Literature DB >> 14736546

The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy.

Lazaros A Nikolaidis1, Anthony Sturzu, Carol Stolarski, Dariush Elahi, You-Tang Shen, Richard P Shannon.   

Abstract

BACKGROUND: The failing heart demonstrates a preference for glucose as its metabolic substrate. Advanced, severe DCM is characterized by depletion of adenosine triphosphate (ATP) stores, which may be a consequence of impaired insulin mediated glucose uptake and oxidation at a time when the myocardium prefers glucose as its substrate. We examined the time course and magnitude of myocardial insulin resistance during the evolution of dilated cardiomyopathy. METHODS AND
RESULTS: Thirty-four conscious, chronically instrumented dogs were studied at four stages during the evolution of dilated cardiomyopathy (DCM) induced by rapid RV pacing [control, early, late and advanced severe]. Transmyocardial glucose, lactate, and non-esterified fatty acid (NEFA) concentrations were measured in the fasting state. The cellular insulin signaling cascade and ATP levels were measured on myocardial samples. NEFA and insulin concentrations increased early and progressively in DCM in association with increased norepinephrine concentrations and progressive hemodynamic impairment. In advanced DCM but not earlier stages, myocardial ATP levels were decreased by 34%. There was decreased myocardial glucose uptake evident under both basal (-29 +/- 5%) and insulin stimulated (-32 +/- 4%) conditions in advanced, severe DCM, associated with a 31% reduction in GLUT-4 translocation. Importantly, there were no alterations in proximal steps in insulin signaling, but significant reductions in serine (Ser473) phosphorylation of Akt-1.
CONCLUSIONS: Advanced, severe DCM is associated with the development of myocardial insulin resistance. There is impaired myocardial glucose uptake and altered myocardial insulin signaling, involving decreased Ser 473 phosphorylation of Akt-1. Myocardial insulin resistance in advanced, severe DCM was also associated with reduced myocardial ATP levels.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14736546     DOI: 10.1016/j.cardiores.2003.11.027

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  47 in total

Review 1.  Targeting myocardial substrate metabolism in heart failure: potential for new therapies.

Authors:  Hossein Ardehali; Hani N Sabbah; Michael A Burke; Satyam Sarma; Peter P Liu; John G F Cleland; Aldo Maggioni; Gregg C Fonarow; E Dale Abel; Umberto Campia; Mihai Gheorghiade
Journal:  Eur J Heart Fail       Date:  2012-02       Impact factor: 15.534

Review 2.  Heart failure and loss of metabolic control.

Authors:  Zhao V Wang; Dan L Li; Joseph A Hill
Journal:  J Cardiovasc Pharmacol       Date:  2014-04       Impact factor: 3.105

3.  Improved diabetic control in advanced heart failure patients treated with left ventricular assist devices.

Authors:  Nir Uriel; Yoshifumi Naka; Paolo C Colombo; Maryjane Farr; Sang-Woo Pak; Vlad Cotarlan; Jeanine B Albu; Dympna Gallagher; Donna Mancini; Henry N Ginsberg; Ulrich P Jorde
Journal:  Eur J Heart Fail       Date:  2010-11-23       Impact factor: 15.534

Review 4.  Cardiogenic diabetes.

Authors:  Maya Guglin; Arnaldo Villafranca; Anthony Morrison
Journal:  Heart Fail Rev       Date:  2014-09       Impact factor: 4.214

5.  Metabolomic analysis of pressure-overloaded and infarcted mouse hearts.

Authors:  Brian E Sansbury; Angelica M DeMartino; Zhengzhi Xie; Alan C Brooks; Robert E Brainard; Lewis J Watson; Andrew P DeFilippis; Timothy D Cummins; Matthew A Harbeson; Kenneth R Brittian; Sumanth D Prabhu; Aruni Bhatnagar; Steven P Jones; Bradford G Hill
Journal:  Circ Heart Fail       Date:  2014-04-24       Impact factor: 8.790

Review 6.  GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study.

Authors:  Kenneth B Margulies; Kevin J Anstrom; Adrian F Hernandez; Margaret M Redfield; Monica R Shah; Eugene Braunwald; Thomas P Cappola
Journal:  Circ Heart Fail       Date:  2014-07       Impact factor: 8.790

Review 7.  Modulating fatty acid oxidation in heart failure.

Authors:  Vincenzo Lionetti; William C Stanley; Fabio A Recchia
Journal:  Cardiovasc Res       Date:  2011-02-02       Impact factor: 10.787

Review 8.  Cardiovascular effects of incretin-based therapies.

Authors:  Michael Lehrke; Nikolaus Marx
Journal:  Rev Diabet Stud       Date:  2011-11-10

9.  Association of heart failure severity with risk of diabetes: a Danish nationwide cohort study.

Authors:  Malene N Demant; Gunnar H Gislason; Lars Køber; Allan Vaag; Christian Torp-Pedersen; Charlotte Andersson
Journal:  Diabetologia       Date:  2014-05-22       Impact factor: 10.122

Review 10.  Animal models of insulin resistance and heart failure.

Authors:  Mauricio Velez; Smita Kohli; Hani N Sabbah
Journal:  Heart Fail Rev       Date:  2014-01       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.